Elevated plasma IgG is associated with improved treatment response and survival in advanced non‑small cell lung cancer patients treated with anti‑PD‑1 therapy.

In the anti-PD-1 monotherapy cohort, there was a trend toward longer OS in patients with an IgG increase (post-/pre-IgG > 1.0) compared with those without an increase (HR 0.37, 95% CI 0.13–1.03; p = 0.0565), but this did not reach statistical significance (Supplementary Fig. 6 B).

also in 111,027 other papers